Mizagliflozin

Mizagliflozin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number	123456-78-9
PubChem	12345678
DrugBank
ChemSpider	12345678
KEGG

Mizagliflozin is a pharmaceutical compound that belongs to the class of sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors). It is primarily used in the management of type 2 diabetes mellitus by promoting the excretion of glucose through the urine, thereby lowering blood glucose levels.

Mechanism of Action

Mizagliflozin works by inhibiting the SGLT2 protein in the proximal tubules of the kidney. SGLT2 is responsible for the reabsorption of glucose from the glomerular filtrate back into the bloodstream. By blocking this transporter, mizagliflozin reduces glucose reabsorption, leading to increased glucose excretion in the urine (glycosuria) and a subsequent reduction in blood glucose levels.

Pharmacokinetics

Mizagliflozin is administered orally and is absorbed in the gastrointestinal tract. It has a bioavailability of approximately 60-70%. The drug is metabolized primarily in the liver and excreted via the kidneys. The half-life of mizagliflozin is approximately 12-14 hours, allowing for once-daily dosing.

Clinical Use

Mizagliflozin is indicated for the treatment of type 2 diabetes mellitus in adults. It is often used in combination with other antidiabetic agents such as metformin or insulin to achieve better glycemic control. The drug is particularly beneficial for patients who are overweight or have cardiovascular risk factors, as it has been shown to promote weight loss and reduce blood pressure.

Side Effects

Common side effects of mizagliflozin include urinary tract infections, genital mycotic infections, and increased urination. These are related to the increased glucose concentration in the urine. Rare but serious side effects include ketoacidosis and acute kidney injury.

Contraindications

Mizagliflozin is contraindicated in patients with severe renal impairment, end-stage renal disease, or those on dialysis. It should also be used with caution in patients with a history of recurrent urinary tract infections or genital infections.

Research and Development

Mizagliflozin is currently undergoing clinical trials to evaluate its efficacy and safety in various populations, including those with chronic kidney disease and heart failure. Ongoing studies are also exploring its potential benefits in reducing cardiovascular events in diabetic patients.

Also see

• Sodium-glucose co-transporter 2 inhibitors
• Type 2 diabetes mellitus
• Metformin
• Insulin
• Ketoacidosis

Template:SGLT2 inhibitors